Implementing remote monitoring for COVID-19 patients in 1

primary care 2

- Svea Holtz^{1,a}, Susanne M. Köhler^{1,a,*}, Peter Jan Chabiera¹, Nurlan Dauletbaev^{2,3,4,5}, Kim 3
- Deutsch⁶, Zoe Oftring^{6,11}, Dennis Lawin⁷, Lukas Niekrenz⁸, Teresa Euler⁹, Rainer Gloeckl¹⁰, 4
- Rembert Koczulla¹⁰, Gernot Rohde⁹, Michael Dreher⁸, Claus F. Vogelmeier², Sebastian 5
- Kuhn^{6,11,a} and Beate Sigrid Müller^{1,12,a} 6
- ¹Goethe University Frankfurt, Institute of General Practice, 60590 Frankfurt am Main, 7
- Germany 8
- ² Department of Internal, Respiratory and Critical Care Medicine, Philipps University of 9
- Marburg, 35043 Marburg, Germany 10
- ³ Department of Pediatrics, McGill University, Montreal, QC H4A 3J1, Canada 11
- ⁴ The Research Institute of McGill University Health Centre, Montreal, QC H4A 3J1, Canada 12
- ⁵ al-Farabi Kazakh National University, Almaty 050040, Kazakhstan 13
- ⁶ Department of Digital Medicine, Medical Faculty OWL, Bielefeld University, 33615 14
- Bielefeld, Germany 15
- ⁷ Department of Cardiology and Intensive Care Medicine, University hospital OWL of 16
- Bielefeld University, Campus Klinikum Bielefeld, Bielefeld, Germany 17
- ⁸ Department of Pneumology and Intensive Care Medicine, University Hospital Aachen, 18
- 52074 Aachen, Germany 19
- ⁹ Goethe University Frankfurt, University Hospital, Medical Clinic 1, Department of 20
- Respiratory Medicine, 60590 Frankfurt am Main, Germany 21
- ¹⁰ Schoen Clinic Berchtesgadener Land, Institute for Pulmonary Rehabilitation Research, 22
- 83471 Schoenau am Koenigssee, Germany 23
- ¹¹ Institute of Digital Medicine, Philipps University of Marburg, 35043 Marburg, Germany 24
- ¹² Institute of General Practice, University of Cologne, Faculty of Medicine and University 25
- Hospital Cologne, 50937 Cologne, Germany 26
- *Correspondence: Dr. Susanne M. Köhler, Institut für Allgemeinmedizin, Theodor-Stern-Kai 27
- 7, 60590 Frankfurt am Main, Germany, koehler@allgemeinmedizin.uni-frankfurt.de 28
- ^a Sherfing first in utbors hip and shared last and beer review and should not be used to guide clinical practice. 29

30 Abstract

31 Background

In Germany, most patients with coronavirus disease 2019 (COVID-19) are treated in an 32 outpatient setting. To improve assessments of the health status of COVID-19 outpatients, 33 various remote monitoring models have been developed. However, little information exists 34 on experiences acquired with remote monitoring in an outpatient setting, particularly from a 35 patient perspective. The aim of our 'COVID-19@home' study was therefore to implement 36 and evaluate an app-based remote monitoring concept for acute and post-acute COVID-19-37 patients in primary care. In this paper, we focus on the patients' evaluation of our remote 38 monitoring approach. 39

40 Methods

Patients with acute COVID-19 measured heart rate, blood pressure, oxygen saturation, and 41 body temperature daily for 28 days. Patients with post-acute COVID-19 determined the 42 same parameters for 12 weeks, supplemented by lung parameters and daily step count. The 43 data were documented using the 'SaniQ' smartphone app. COVID-19 symptoms were 44 assessed daily using an app-based questionnaire. Patients' GPs could access the data on the 45 'SaniQ Praxis' telemedicine platform. We used an app-based questionnaire consisting of 11 46 guestions presented with a 4-point Likert scale to evaluate patient satisfaction. Data were 47 analyzed descriptively. 48

49 Results

Of the 51 patients aged 19-77 years that participated in the study, 42 completed the questionnaire. All patients rated home monitoring as 'very good' or 'rather good' and were able to integrate the measuring processes into their daily routines. Overall, 93% would recommend the app and the measuring devices to their family and friends. About 60% felt that their COVID-19 treatment had benefited from home monitoring. Only few patients were unsettled by the app and use of the measuring devices. During the course of the study, the implementation process was optimized.

57 **Conclusions**

The use of remote monitoring in COVID-19 patients is feasible and was evaluated positively by most study patients. However, it is difficult to imagine how general practices could cope with monitoring patients with acute diseases without any further organizational support.

- ⁶¹ Future research should address cost-effectiveness and changes in such clinical outcomes as
- 62 hospitalization and mortality.

63 Keywords

⁶⁴ Primary Health Care; telemedicine; COVID-19; mobile applications; patient satisfaction

65 **1. Introduction**

In Germany, the majority of patients with a severe acute respiratory syndrome coronavirus 2 66 (SARS-CoV-2) infection are treated in an outpatient setting. This was true for 6/7 patients in 67 the first phase of the pandemic and thereafter for 32/33 patients, as a result of milder 68 disease courses in vaccinated patients [1]. While most patients present with mild or 69 moderate symptoms [2], some develop severe clinical outcomes and require hospitalization. 70 Despite receiving such treatment as invasive mechanical ventilation, or kidney replacement 71 therapy, some of these patients may die [3]. The early identification of patients showing 72 preliminary signs of deterioration is therefore crucial, since early interventions, including 73 hospitalization, are associated with better outcomes and prognoses [4]. Furthermore, the 74 severity of symptoms may not adequately reflect organ damage, especially as coronavirus 75 disease 2019 (COVID-19) is sometimes associated with 'silent hypoxia', an abrupt and 76 initially asymptomatic drop in oxygen saturation [5, 6]. Standardized monitoring of blood 77 oxygen saturation is expected to enable the timely recognition of patients requiring 78 treatment escalation [6-8]. 79 80 To better assess the health status of outpatients with COVID-19, health care providers in several countries reacted to the global outspread of SARS-CoV-2 by applying remote 81 monitoring solutions [9, 10]. Some providers, for example, used (video) phone-calls to gather 82

information, while others developed mobile applications (apps) to collect data on vital signs
[9]. However, both general practitioners and patients have little experience of using remote
monitoring for acute diseases [11].

We therefore initiated the 'Covid-19@home' study, with the aim of implementing and evaluating a remote monitoring concept for COVID-19-patients, i.e. patients with an acute disease, in primary care. We used the 'SaniQ' app and the corresponding 'SaniQ Praxis' telemonitoring platform [12]. In this paper, we focus on participating patients' adherence and their evaluation of our approach to remote monitoring, as well as the optimization of the implementation process.

92 2. Methods

93 Study design and setting

We conducted a prospective observational study (COVID-19@home) in Frankfurt, Germany.
 The study was carried out from January to December 2021, whereby the period from

- January 2021 to July 2021 was a pilot phase to optimize the implementation process. The 96 data presented in this study were collected between January and November 2021. For this 97
- paper, we followed STROBE reporting guidelines for cohort studies, where applicable [13]. 98

Study registration and ethical approval 99

COVID-19@home was part of the egePan Unimed project, and one of the thirteen projects 100

- that make up 'Netzwerk Universitätsmedizin' [14]. It was registered in the German Clinical 101
- Trials Register (DRKS00024604, https://www.drks.de/drks_web/setLocale_EN.do, 102
- 103 26.04.2021). The study was approved by the Ethics Committee of Goethe University
- Frankfurt (No. 20-1023, 18.01.2021), and written informed consent was obtained from all 104
- 105 participants.

GPs 106

Eight GPs participated in the study. Seven of them belonged to a research network of 107 108 general practices in Hesse, Germany (ForN) and were recruited after participating in a virtual network meeting. One GP agreed to participate after receiving an invitation to participate by 109 mail. All GPs provided written informed consent prior to study participation. Qurasoft 110 GmbH, Koblenz, Germany, provided each GP with his or her own password-protected user 111 account for version 1.x of the SaniQ Praxis telemonitoring platform free of charge. Before 112 recruiting patients, each GP attended a 30-minute one-on-one online training session on 113 how to use the platform. The session was conducted by the software company Qurasoft 114 GmbH using Microsoft Teams software. GPs did not receive any compensation for their 115 participation. 116

Patients 117

Participating GPs asked patients that had had a PCR test for COVID-19 at their practice if 118 they wished to participate. They were included in the study if their PCR test result was 119 positive (acute COVID-19 patients). Patients that were being treated by their GPs for 120 persistent COVID-19 symptoms (post-acute COVID-19 patients) were also asked if they 121 wanted to participate. Patients had to be aged \geq 18 years and have access to a smartphone 122 that they, or someone in the same household, was able to use. GPs decided which patients 123 to invite. They handed out a flyer that contained information on the study, and the phone 124 number and email address of the study team. Patients could then contact the study team via 125 telephone or email if they were interested in participating. The study team at the Institute of 126 General Practice at Goethe University Frankfurt answered all questions by telephone. 127

Patients received detailed written study information and were required to give their written 128 informed consent. They were also informed that neither the study team nor the treating GP 129 provided 24/7-supervision, and that they were required to monitor their vital signs 130 themselves. In case of medical queries, patients were advised to call their GPs or the 131 emergency services. They were further required to confirm that they had understood these 132 conditions on the consent form. Study participation was voluntary and could be terminated 133 at any time. The patients received no monetary compensation but were permitted to keep 134 the measuring devices. 135

136 Measuring devices and patient app

The patients received the required measuring equipment within 48 hours of inclusion in the 137 study, so they could quickly begin monitoring their vital signs. Acute COVID-19 patients 138 received a pulse oximeter, a blood pressure monitor, and a non-contact thermometer, while 139 post-acute patients additionally received a peak flow and FEV1 meter, and an activity sensor 140 (see table 1). Patients were also provided with two codes to activate and authorize the 141 smartphone app 'SaniQ' (module 'Infekt'). All equipment was provided free of charge. After 142 installing the app and entering the activation code, the patients used the devices to measure 143 their health parameters. Data were entered into the app manually, or transmitted from the 144 devices via Bluetooth[®]. The app was used to document the measured data and patients 145 could view the data in the app (raw data and graphs), enabling them to monitor the course 146 of the disease themselves. When a health parameter fell outside the normal range, the app 147 sent an in-app notification or email to the patient (alert) stating that, for example, 'The 148 measured value for your heart rate is outside the normal range. Please repeat the 149 measurement. In case of uncertainty, contact your GP practice, or the emergency services.' 150 During business hours, the study team could be reached on the telephone to answer 151 questions that were unrelated to health. Additionally, the app and platform provider 152 (Qurasoft GmbH) provided a hotline for technical problems. 153

154 **Table 1.** Measuring devices used in the study

Device	Image	Model
Pulse oximeter	[12]	Beurer PO 60 pulse oximeter, Beurer GmbH, Ulm, Germany
Blood pressure monitor	[12]	Aponorm Basis Plus Bluetooth, WEPA APOTHEKENBEDARF GmbH & Co KG, Montabaur, Germany
Non-contact thermometer	[12]	Beurer FT 95 non-contact thermometer, Beurer GmbH, Ulm, Germany
Peak flow and FEV1 meter	[12]	Smart One, MIR - Medical International Research s.r.l., Rome, Italy
Activity sensor	I [12]	Beurer AS 99 Activity Tracker, Beurer GmbH, Ulm, Germany

155 **Remote monitoring platform**

By entering an authorization code, patients could link their account to their GP's 'SaniQ 156 Praxis' account, thus permitting them to view their data. Developments in their vital signs 157 were displayed as a list or graph. GPs decided individually – i.e. according to a patient's risk 158 profile and the course of the disease - how often to check a patient's data. Upper and lower 159 limits for the vital signs were defined in accordance with standard operating procedures 160 (SOPs) of participating pneumology departments and the COVID-19 treatment 161 recommendations available at the time [15] (see supplementary material table S.1). GPs 162 could also tailor these predefined limits to suit the needs of individual patients. If a vital sign 163 was outside the limits, the patient's GP received an automatic email from 'SaniQ Praxis' 164 informing him or her accordingly. The GP could then check the available data on the 165

- ¹⁶⁶ platform and contact the patient if necessary. The optional alarm function could be
- 167 deactivated by GPs for each individual patient.
- 168 **Data collection**
- 169 a. Measurements
- ¹⁷⁰ For 28 days, acute patients measured their heart rate, blood pressure, SpO₂, and body
- temperature once a day. Post-acute patients determined the same vital signs for 12 weeks,
- supplemented by lung parameters (peak flow [PEF], forced expiratory pressure in 1 second
- 173 [FEV1]) and activity parameters (daily step count).
- 174 b. Questionnaires
- 175 Patients filled in three in-app questionnaires consisting of questions relating to their medical
- 176 history, daily symptoms and views on remote monitoring:
- 177 The medical history questionnaire included questions on current COVID-19 symptoms,
- relevant pre-existing medical conditions and current medication. Overall, the medical history
- 179 questionnaire consisted of 35 questions requiring yes or no answers (see supplementary
- 180 material table S.2) and was developed on the basis of available publications [16–19]. As the
- 181 pandemic was evolving rapidly and studies in an ambulatory setting were urgently needed,
- the first patients were included while the questionnaire was still under development. The
- 183 study team therefore took the medical history of the first 22 patients by phone, and filled in
- 184 their medical history questionnaires retrospectively. In response to new research findings
- 185 (e.g. skin rashes), further questions on symptoms were added later.
- 186 The second questionnaire consisted of seven questions on the most common COVID-19
- 187 symptoms. It was based on the SOPs of participating pneumology departments, DEGAM
- recommendations, and validated questionnaires on fatigue and shortness of breath [20–22].
- 189 Patients received the questionnaire daily for the duration of their participation in the study.
- 190 After completion of the study, patients were asked to fill in an evaluation questionnaire that
- asked about their experiences and satisfaction with remote monitoring (see supplementary
- ¹⁹² material table S.3). The 11 questions were presented with a 4-point Likert scale and based
- ¹⁹³ on validated questionnaires on telemedicine satisfaction and telehealth usability [23–26].
- 194 Patients that stopped taking measurements before completing the study also received an
- evaluation questionnaire and, if necessary, a telephone or email reminder at the end of thestudy period.

197 Data analysis

A certified server hosted in Germany was used as an online platform to store all data. Patient data were exported from the platform in a comma-separated values (csv) format. Personal data were pseudonymized before analysis. We used Microsoft Excel 2016 to descriptively analyze the data. Continuous variables such as age are provided with their mean and standard deviation, while absolute and relative frequencies are provided for discrete data. The results also include information on the sample size n.

204 **3. Results**

205 Sample Characteristics

Overall, 51 outpatients participated in the COVID-19@home study, of whom 32 were acute 206 COVID-19 patients and 19 post-acute patients. Patients were between 19 and 77 years old, 207 and their mean age was 48.7 (SD: 12.5). Thirty women (58.8%) and 21 men (41.2%) 208 participated. Eight (15.7%) patients were obese (body mass index 30 or more). Information 209 on further pre-existing conditions were provided by 48 patients (94.1%), of whom 10 (20.8%) 210 had one risk factor for a potentially severe course of COVID-19, eight (16.7%) had two, and 211 three (6.3%) had three risk factors. Eight patients had cardiovascular disease (16.7%), while 212 six each had diabetes mellitus or lung disease (12.5%). The patients reported a mean of 4.2 213 symptoms upon study inclusion (SD: 2.8, minimum: 0, maximum: 11) (see table 2). 214

Questionnaire Item	Acute patients			Post-acute	Post-acute patients		
	n (total)¹	n ²	%	n (total) ¹	n ²	%	
Number of symptoms upon	31		100	19		100	
study inclusion							
• 0		о	0.0		7	36.8	
• 1-3		10	32.3		4	21.1	
• 4-6		13	41.9		6	31.6	
• 7-9		7	22.6		2	10.5	
• ≥10		1	3.2		0	0.0	

Table 2. COVID-19 symptoms (n=50)

All rights reserved. No reuse allowed without permission.

Lethargy/exhaustion	29	26	89.7	19	10	52.6
Headache/dizziness	10	8	80.0	19	7	36.8
Cough	31	23	74.2	19	4	21.1
Pain in muscles/joints	28	20	71.4	19	4	21.1
Difficulty concentrating	10	5	50.0	19	8	42.1
Head cold	29	12	41.4	19	3	15.8
Sore throat	30	12	40.0	19	3	15.8
Gastro-intestinal complaints	30	12	40.0	19	0	0.0
Fever/chills	31	11	35.5	19	1	5.3
Smell/taste impairment	30	11	36.7	19	6	31.6
Breathing difficulties	30	9	30.0	19	4	21.1
Chest pain	30	6	20.0	19	0	0.0
Skin rash	26	3	11.5	19	2	10.5

²¹⁶ ¹n (total): number of patients being asked about symptoms. Differences in n (total) reflect

regular updates to the medical history questionnaire.

²n: number of patients with symptoms.

219 Participation

Acute patients started taking measurements 1 to 26 days after receiving their positive PCR

test result, or an average of 5.7 days (SD: 5.7). Patients with post-acute symptoms began 22

to 447 days after receiving their positive PCR test result (mean: 152.4, SD: 112.6).

Adherence to daily measuring was high, with 93.8% of acute patients and 89.5% of post-

acute patients measuring vital signs as intended. The overall dropout rate was 7.8% (four

patients).

226 Evaluation

Overall, 48 patients received the evaluation questionnaire and 42 (87.5%) completed it. Of

the respondents, 31 (73.8%) had 'rarely' or 'never' recorded their health data before.

Nevertheless, 39 patients, or 92.9% 'completely agreed' or 'partially agreed' that they had

managed to cope with using the app and measuring devices. All 42 respondents (100%)

²³¹ 'completely agreed' or 'partially agreed' that they 'could comfortably integrate

measurement-taking' into their daily routines. Overall, 34 patients (81.0%) managed to deal

with the app and devices on their own and 'rarely' or 'never' required aid in using them. Use

of the app and measuring devices rarely seemed to have unsettled users: 38 (90.5%) of our

cohort 'partially disagreed' or 'disagreed' that they had 'experienced uncertainty when using

- the app and measuring devices'.
- 237 Twenty-five patients (59.5%) agreed that treatment of their COVID-19 illness had benefited
- ²³⁸ from remote monitoring. Patients' overall opinion of remote monitoring was very positive,
- with all 42 respondents describing it as 'very good' or 'rather good' (100%). Moreover, 39 of
- them (92.9%) would recommend the app and measuring devices to their family and friends
- 241 (see table 3 for more details).

Questionnaire Item	n	%
Previous experience of recording healt	h data	
Regularly	6	14.3
Sometimes	5	11.9
Rarely	8	19.0
Never	23	54.8
Coped with using the app and measur	ing devices	
Completely agreed	30	71.4
Partially agreed	9	21.4
Partially disagreed	3	7.1
Completely disagreed	0	0
Easy integration into everyday life		
Completely agreed	27	64.3
Partially agreed	15	35.7
Partially disagreed	0	0
Completely disagreed	0	0
Required aid in using the app and mea	suring devices	I
Regularly	3	7.1
Sometimes	5	11.9
Rarely	6	14.3
Never	28	66.7

Table 3. Evaluation of 'SaniQ' app and measuring devices (n = 42)

perpetuity. All rights reserved. No reuse allowed without permission.

Completely agreed	12	28.6
Partially agreed	13	31.0
Partially disagreed	13	31.0
Completely disagreed	4	9.5
Experienced uncertainty when using th	e app and measuring devic	es
Completely agreed	0	0
Partially agreed	4	9.5
Partially disagreed	10	23.8
Completely disagreed	28	66.7
Overall assessment of remote monitor	ing	
Very good	30	71.4
Rather good	12	28.6
Rather poor	0	0
Very poor	0	0
Recommendation of app to friends and	l family	
Yes	34	81.0
Yes, probably	5	11.9
No, probably not	3	7.1
No	0	0

243

244 Changes to the implementation process

In order to include acute patients as quickly as possible the study team put on full protection

gear to avoid infection and handed over the consent forms and measuring devices in person.

Afterwards, consent forms were returned via email. The measuring devices were sent to

patients via express mail, as this proved to be reliable and fast enough (delivery within 48

249 hours).

²⁵⁰ We also distributed a detailed manual provided by the software partner, which resulted in a

sharp drop in the number of calls due to technical problems.

As the pandemic was evolving rapidly and studies were urgently needed in an ambulatory

setting, we started enrolling patients in January 2021, even though the development of our

in-app questionnaires had not yet been finalized. During the pilot phase, we took patients'

²⁵⁵ medical histories and gathered information on their COVID-19 symptoms by telephone.

Further questions on symptoms were added when new research findings were published
 (e.g. gastro-intestinal complaints, skin rashes). The evaluation questionnaire was presented
 to 48/51 patients.

4. Discussion

260 Main findings

We implemented a remote monitoring concept for COVID-19 outpatients. Patients used the included app to self-monitor their vital parameters and symptoms daily. GPs could then view the results on a software platform. Patient adherence was high with 93.8% of acute patients and 89.5% of post-acute patients measuring vital signs as intended. All patients that completed an evaluation questionnaire rated the app as 'very good' or 'rather good'. Almost all patients would recommend the app and measuring devices to their families and friends. We optimized the implementation process during the pilot phase.

268 Findings in relation to the literature

²⁶⁹ Our study is one of only a few to focus on patients' use of remote monitoring to

communicate with their GP practice [27]. In contrast to other studies and in order to gain

²⁷¹ broad experience, we included patients of all ages and with any pre-existing conditions.

272 Several studies on remote monitoring have, however, investigated COVID-19 patients that

required ongoing supervision and treatment in secondary settings, such as pre-admission

wards, virtual wards, or that were receiving care in a 'hospital at home' (following an early

release from hospital) [9, 28, 29]. Some studies included all patients suspected of having

276 COVID-19, regardless of their PCR test results [30]. In our study, however, a positive PCR

result was an inclusion criterion, which allowed us to focus on COVID-19 patients and their

specific needs (e.g., self-isolation at home).

enrolment data [9].

286

International studies on remote monitoring generally used pulse oximetry, while only a few used non-contact thermometers and blood pressure monitors [9, 28]. Telephone-, app- and paper-based protocols were used for data transfer [9, 28, 31, 32]. We decided to use an app to ensure instant documentation and data transfer, a low risk of transmission errors, and greater opportunities for data analysis. We managed to enrol acute COVID-19 patients quickly, and included them in our study a median of 3.5 days after a positive PCR test result. While other studies also emphasized the importance of speed, they provided no exact

13

Several authors have concluded that remote monitoring cannot be successful unless 287 patients' needs are taken into account [7, 28]. A lack of patient training, technical barriers, 288 and insufficient usability appear to explain most patient dropouts [11, 28, 33]. In our study, 289 some patients experienced initial difficulties installing the app and connecting the measuring 290 devices. We therefore added a detailed manual to emails and packages containing the 291 devices. This resulted in a sharp drop in the number of calls due to technical problems, and 292 the overall dropout rate was low (7.8%). Patients' evaluations indicate that our remote 293 monitoring concept is suitable for patients that have no experience of recording health data. 294 However, patients without German language skills could not participate in our remote 295 monitoring program, unlike some remote home monitoring models in the UK that developed 296 culturally appropriate patient information in different languages [28]. 297 Our patients were advised to monitor their vital signs 'at least once a day'. However, the 298 frequency with which they measured them varied. This complicated data management, 299 analysis and interpretation. We would therefore recommend specifying frequency more 300 precisely in future studies. It might also be appropriate to adjust the frequency of 301 measurements over the course of the disease and to intensify it in high-risk acute COVID-19 302 patients, as was the case in a study on remote monitoring conducted in Tuscany [34]. To 303 raise compliance, post-acute patients might also be asked to take their measurements less 304 often, e.g. three times a week. 305

306 Strengths and limitations

Despite the relatively small sample size, our study provides real-world experience from patients who used the app intensively over a long period of time. They were thus able to accumulate considerable experience of remote monitoring, which increased the informative value of our evaluation results.

However, our study also has several limitations. As our questionnaires were still under 311 development when the pilot phase began, they were partially conducted on the telephone 312 313 and partially via the app itself. Furthermore, the medical history questionnaire evolved throughout the study to take account of new scientific findings on COVID-19 symptoms, 314 limiting the generalizability of our results. In addition, we did not use a validated 315 questionnaire, and several adjustments were made to the implementation process during 316 the course of the study. At the beginning of the study, for example, we wore full protective 317 gear to avoid infection and provided the consent forms and measuring devices in person. 318

Afterwards, consent forms were distributed and collected via email, and measuring devices were sent to patients using express mail. As a result, the processes assessed by the patients were not identical, which may have limited the validity of our results.

However, as these modifications mainly concerned organizational processes, and the self-322 monitoring process remained unchanged, we would expect their influence on the evaluation 323 to have been small. As guarantine limited technical support options, our approach to remote 324 monitoring was only suitable for patients that owned a smartphone and were familiar with 325 installing and using apps. It was therefore impossible to include persons that were unable to 326 use the technical infrastructure. This also applied to people with language barriers or 327 disabilities that would have prevented them from using the app and devices. In future 328 research, attempts should be made to make remote monitoring possible for these people, 329 too. Future research should also address cost-effectiveness and changes in such clinical 330 outcomes as hospitalization and mortality, which we did not consider. 331

332 **5.** Conclusion

In this study, we implemented remote monitoring among COVID-19 outpatients and 333 iteratively optimized our approach during a pilot phase. During the implementation process, 334 we learned that the success of remote monitoring depends on certain conditions being 335 fulfilled. First, non-contact delivery of measuring devices should be arranged for acute 336 COVID-19 patients as soon as possible after the disease is diagnosed. Second, patients need 337 precise and comprehensive instructions on how to correctly install and use the app and 338 measuring devices. Patients' evaluations indicate that most patients then accepted and were 339 able to use remote monitoring as we intended. Third, as some patients initially experienced 340 technical difficulties, background support was required to ensure both patient adherence 341 and that the system worked as planned. However, it is difficult to imagine how general 342 practices could cope with these additional tasks. Sufficient patient and practice support 343 should therefore be provided if the model is to be implemented on a larger or even 344 nationwide scale. 345

346 Acknowledgments

The authors would like to express their thanks to all participating patients and GPs. We are
also grateful to Phillip Elliott for the language review of the paper.

349 Funding

350 This research was funded by the German Federal Ministry of Education and Research, BMBF,

351 grant number 01KX2021.

352 Competing interest statement

The institutions of S.H., S.M.K., P.J.C., N.D., L.N., T.E., R.G., R.K., G.R., M.D., C.F.V. and B.S.M 353 received funding for this study from the German Federal Ministry of Education and 354 Research, BMBF, grant number 01KX2021. The funder had no role in the design of the study; 355 in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in 356 the decision to publish the results. P.J.C. is an employee at OncologyInformationService e.K. 357 N.D. has received the CSL Behring award 'Translational Research on Extracellular Vesicles in 358 COPD'. R.K. and R.G. have been involved in projects and publications using the Kaia COPD 359 App. SK is founder and managing partner of MED.digital GmbH. He holds shares of BioNTech, 360 Pfizer, and CRISPR Therapeutics. He is member of the commission 'New Professions' of 361 Stiftung Münch and of several committees of the German Medical Association 362 ('Digitalization of health care' and 'Medical Education and University Medicine'). B.S.M. has 363

- received personal honoraria for scientific consultancy to health insurance fund 'Die
- ³⁶⁵ Techniker'. The remaining authors declare no conflict of interest.

366 Availability of data and materials

The datasets generated and analyzed during the study are available from the corresponding
 author on reasonable request.

369 **References**

- 1. KBV. Ambulante Versorgung in der Corona-Pandemie.
- 371 https://www.kbv.de/media/sp/Ambulante_Versorgung_Corona_Pandemie_Zahlen_Fakt
- en.pdf. Accessed 9 Nov 2022.
- 2. Neef V, Piekarski F, Zacharowski K, Raimann FJ. SARS-CoV-2-Pandemie eine Meta-
- Analyse zur Klinik, Diagnostik und Therapie der Infektion. Anästh Intensivmed.
- 375 **2020;61:480–91. doi:10.19224/ai2020.480.**
- 376 3. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
- 377 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients

Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323:2052–9.

doi:10.1001/jama.2020.6775.

380 4. Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med.

³⁸¹ 2020;383:1757–66. doi:10.1056/NEJMcp2009249.

382 5. Rahman A, Tabassum T, Araf Y, Al Nahid A, Ullah MA, Hosen MJ. Silent hypoxia in COVID-

19: pathomechanism and possible management strategy. Mol biol rep. 2021;48:3863–9.
 doi:10.1007/s11033-021-06358-1.

- Levitan RM. Pulse Oximetry as a Biomarker for Early Identification and Hospitalization of
 COVID-19 Pneumonia. Acad Emerg Med. 2020;27:785–6. doi:10.1111/acem.14052.
- 7. Greenhalgh T, Knight M, Inda-Kim M, Fulop NJ, Leach J, Vindrola-Padros C. Remote

management of covid-19 using home pulse oximetry and virtual ward support. BMJ.
2021;372:n677. doi:10.1136/bmj.n677.

- 390 8. Shah S, Majmudar K, Stein A, Gupta N, Suppes S, Karamanis M, et al. Novel Use of Home
- ³⁹¹ Pulse Oximetry Monitoring in COVID-19 Patients Discharged From the Emergency
- ³⁹² Department Identifies Need for Hospitalization. Acad Emerg Med. 2020;27:681–92.
- 393 doi:10.1111/acem.14053.
- ³⁹⁴ 9. Vindrola-Padros C, Singh KE, Sidhu MS, Georghiou T, Sherlaw-Johnson C, Tomini SM, et
- al. Remote home monitoring (virtual wards) during the COVID-19 pandemic: a

³⁹⁶ systematic review. medRxiv. 2020:2020.10.07.20208587.

- doi:10.1101/2020.10.07.20208587.
- 10. Bokolo AJ. Use of Telemedicine and Virtual Care for Remote Treatment in Response to
- 399 COVID-19 Pandemic. J Med Syst. 2020;44:132. doi:10.1007/s10916-020-01596-5.

11. Flodgren G, Rachas A, Farmer AJ, Inzitari M, Shepperd S. Interactive telemedicine: effects

- 401 on professional practice and health care outcomes. Cochrane Database Syst Rev.
- 402 2015:CD002098. doi:10.1002/14651858.CD002098.pub2.
- 12. SaniQ. 2022. https://saniq.org/. Accessed 22 Mar 2022.
- 13. Elm E von, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The
- 405 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
- 406 statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–
- 407 9. doi:10.1016/j.jclinepi.2007.11.008.

14. Netzwerk Universitätsmedizin. Projekte. Forschungsarbeiten für die bestmögliche

409 Patientenversorgung. 2022. https://www.netzwerk-universitaetsmedizin.de/. Accessed

410 **5 Dec 2022.**

15. Greenhalgh T, Thompson P, Weiringa S, Neves AL, Husain L, Dunlop M, et al. What items

- should be included in an early warning score for remote assessment of suspected
- 413 COVID-19? qualitative and Delphi study. BMJ Open. 2020;10:e042626.
- 414 doi:10.1136/bmjopen-2020-042626.

15 16. Hüfner A, Kiefl D, Baacke M, Zöllner R, Loza Mencía E, Schellein O, et al.

- 416 Risikostratifizierung durch Implementierung und Evaluation eines COVID-19-Scores : Eine
- 417 retrospektive Diagnostikstudie. [Risk stratification through implementation and

evaluation of a COVID-19 score : A retrospective diagnostic study]. Med Klin Intensivmed

419 Notfmed. 2020;115:132–8. doi:10.1007/s00063-020-00754-4.

17. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of

421 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical

422 Characterisation Protocol: prospective observational cohort study. BMJ.

423 **2020;369:m1985. doi:10.1136/bmj.m1985.**

18. Brian E. Dixon, Kara Wools-Kaloustian, William F. Fadel, Thomas J. Duszynski, Constantin

425 Yiannoutsos, Paul K. Halverson, Nir Menachemi. Symptoms and symptom clusters

associated with SARS-CoV-2 infection in community-based populations: Results from a
 statewide epidemiological study.

19. Patienten-Info zum Coronavirus (SARS-CoV-2): Symptom-Checkliste für SARS-CoV-2.

429 07.06.2022. https://thieme-

430 compliance.de/fileadmin/user_upload/Download/Informationsmaterialien/Coronavirus/

431 de/symptomchecker.html. Accessed 23 Nov 2022.

432 20. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP.

433 Development of a fatigue scale. Journal of Psychosomatic Research. 1993;37:147–53.

434 doi:10.1016/0022-3999(93)90081-P.

435 21. Eakin EG, Resnikoff PM, Prewitt LM, Ries AL, Kaplan RM. Validation of a new dyspnea

436 measure: the UCSD Shortness of Breath Questionnaire. University of California, San

437 Diego. Chest. 1998;113:619–24. doi:10.1378/chest.113.3.619.

438 22. DEGAM. SARS-CoV-2/-Covid-19-Informationen & Praxishilfen für niedergelassene

Hausärztinnen und Hausärzte: S2e-Leitlinie. 2022.

440 https://register.awmf.org/assets/guidelines/053-054l S2e SARS-CoV-2-Covid-19-

441 Informationen-Praxishilfen-Hausaerztinnen-Hausaerzte_2022-02_2.pdf. Accessed 5 Dec
442 2022.

23. Finkelstein SM, MacMahon K, Lindgren BR, Robiner WN, Lindquist R, VanWormer A,

444 Hertz MI. Development of a remote monitoring satisfaction survey and its use in a

clinical trial with lung transplant recipients. J Telemed Telecare. 2012;18:42–6.

446 doi:10.1258/jtt.2011.110413.

24. PARMANTO B, LEWIS AN, GRAHAM KM, BERTOLET MH. Development of the Telehealth
Usability Questionnaire (TUQ). Int J Telerehabil. 2016;8:3–10. doi:10.5195/ijt.2016.6196.

449 25. Ruiz Díaz MA, Egea García M, Muñoz Aguilera R, Viñolas Prat X, Silvestre García J, Álvarez

450 Orozco M, Martínez Ferrer J. Patient satisfaction with remote monitoring of cardiac

⁴⁵¹ implantable electronic devices: the VALIOSA questionnaire. BMC Health Serv Res.

452 **2020;20:354.** doi:10.1186/s12913-020-05216-3.

26. Yip MP, Chang AM, Chan J, MacKenzie AE. Development of the Telemedicine Satisfaction
 Questionnaire to evaluate patient satisfaction with telemedicine: a preliminary study. J
 Telemed Telecare. 2003;9:46–50. doi:10.1258/135763303321159693.

27. Wurzer D, Spielhagen P, Siegmann A, Gercekcioglu A, Gorgass J, Henze S, et al. Remote
 monitoring of COVID-19 positive high-risk patients in domestic isolation: A feasibility
 study. PLoS One. 2021;16:e0257095. doi:10.1371/journal.pone.0257095.

459 28. Vindrola-Padros C, Sidhu MS, Georghiou T, Sherlaw-Johnson C, Singh KE, Tomini SM, et

al. The implementation of remote home monitoring models during the COVID-19

461 pandemic in England. EClinicalMedicine. 2021;34:100799.

462 doi:10.1016/j.eclinm.2021.100799.

29. Motta LP, Da Silva PPF, Borguezan BM, Amaral JLMd, Milagres LG, Bóia MN, et al. An

emergency system for monitoring pulse oximetry, peak expiratory flow, and body

temperature of patients with COVID-19 at home: Development and preliminary

466 application. PLoS One. 2021;16:e0247635. doi:10.1371/journal.pone.0247635.

30. Dirikgil E, Roos R, Groeneveld GH, Heringhaus C, Silven AV, Petrus AHJ, et al. Home

468 monitoring reduced short stay admissions in suspected COVID-19 patients: COVID-box

469 project. Eur Respir J. 2021;58:2100636. doi:10.1183/13993003.00636-2021.

- 470 31. Yordanov Y, Dechartres A, Lescure X, Apra C, Villie P, Marchand-Arvier J, et al. Covidom,
- a Telesurveillance Solution for Home Monitoring Patients With COVID-19. J Med Internet
- 472 Res. 2020;22:e20748. doi:10.2196/20748.
- 473 32. Schinköthe T, Gabri MR, Mitterer M, Gouveia P, Heinemann V, Harbeck N, Subklewe M.
- 474 A Web- and App-Based Connected Care Solution for COVID-19 In- and Outpatient Care:
- 475 Qualitative Study and Application Development. JMIR Public Health Surveill.
- 476 2020;6:e19033. doi:10.2196/19033.
- 477 33. Bardy P. The Human Challenge of Telemedicine: Toward a Time-Sensitive and Person-
- 478 Centered Ethics of Home Telecare. San Diego: ISTE Press Limited Elsevier Incorporated;
 479 2018.
- 480 34. Panicacci S, Donati M, Lubrano A, Vianello A, Ruiu A, Melani L, et al. Telemonitoring in
- the Covid-19 Era: The Tuscany Region Experience. Healthcare. 2021;9:516–27.
- 482 doi:10.3390/healthcare9050516.